Compare Abeona Therapeutics Inc (ABEO) vs Estee Lauder Companies Inc (EL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Estee Lauder Companies Inc — how do they compare? Abeona Therapeutics Inc trades at $6.78 (market cap $373.32M), while Estee Lauder Companies Inc trades at $81.56 (market cap $30.55B). The key difference: Estee Lauder Companies Inc is far larger — about 81.8× Abeona Therapeutics Inc's market cap, and Estee Lauder Companies Inc pays a 1.66% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | EL | |
|---|---|---|
Market Cap | $373.32M | $30.55B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $119.61 |
52-Week Low | $4.17 | $67.23 |
Enterprise Value | $228.22M | $36.72B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Estée Lauder (EL) trades at $84.44, up 0.87% with a bullish technical signal and recent earnings beats. The stock shows strong momentum with three consecutive quarterly EPS beats and a consensus price target of $90.60. However, fundamentals reveal challenges with negative net income of -$1.13B in 2025 and elevated P/E of 147.8, though gross margins remain robust at 74.71%. Recent news highlights strategic investments and product innovation, including the Scent Scanner launch with Jo Malone London.
The outlook is mixed: technical strength and analyst optimism support upside to $90+, but high valuation and profitability concerns pose risks. Investment opportunity lies in execution of growth initiatives and margin recovery, while key risks include competitive pressures and macroeconomic headwinds affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →
